Clene Inc.

Clene (CLNN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

zacks.com - 2026-06-04 10:56:07

Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.5 per share a year ago.

zacks.com - 2026-05-14 10:10:29

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an o versubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturity In May 2026, Clene completed a $7 million underwritten registered direct offering with a single investor SALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late-stage clinical biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2026 financial results and provided recent updates on its CNM-Au8 programs. “We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA and appreciate the Agency's engagement as we advance toward a planned NDA submission for CNM-Au8 under the accelerated approval pathway for patients with ALS,” said Rob Etherington, President and CEO of Clene.

globenewswire.com - 2026-05-14 08:00:00

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at a purchase price of $7.00 per share to a single investor.

globenewswire.com - 2026-05-05 08:45:00

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May. Emerging Growth Conference Date: May 6, 2026 Time of Presentation: 3:25 p.m.

globenewswire.com - 2026-05-05 08:00:00

Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated approval of its ALS treatment following a constructive meeting with the FDA.

benzinga.com - 2026-05-04 11:22:44

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data FDA acknowledged NfL could potentially serve as a reasonably likely surrogate endpoint Clene expects to submit an NDA for CNM-Au8 to the FDA in the third quarter of 2026 CNM-Au8 represents a potential first-in-class therapeutic approach for ALS, a disease area with significant unmet medical need SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) --  Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced receipt of final meeting minutes following its recent Type C meeting with the U.S. Food and Drug Administration (FDA). During the meeting and confirmed in the final meeting minutes, the FDA stated that Clene's “proposed data may be capable of supporting the submission and review of an [New Drug Application (NDA)] under the accelerated approval pathway for the treatment of ALS.

globenewswire.com - 2026-05-04 08:00:00

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $6.40, for a total value of $49,587.20. Following the completion of the sale, the insider owned 387,769 shares in the company, valued

defenseworld.net - 2026-04-20 05:14:51

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of the company's stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $6.48, for a total transaction of $41,303.52. Following the completion of the transaction, the insider owned 395,517 shares in the company,

defenseworld.net - 2026-04-20 05:14:50

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 25,040 shares of Clene stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $6.43, for a total transaction of $161,007.20. Following the completion of the sale, the insider owned 362,729 shares of the company's stock,

defenseworld.net - 2026-04-20 04:26:54